Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE), or lupus, is an autoimmune disease where the immune system mistakenly attacks healthy tissue, leading to a range of symptoms including painful and swollen joints, fever, chest pain, hair loss, mouth ulcers, and a characteristic facial rash. The condition is characterized by periods of flares and remission, and certain supplements may help improve the quality of life for those affected.
Health Outcomes
- Accelerated Recovery in Immunocompromised Mice
- Achieved Inflammation Homeostasis
- Activated Immune Response
- Adjusted Immune Function
- Altered CD4+ T-cell Cytokine Levels
- Altered CD4+/CD8+ Ratio
- Altered Expression of Immune Products
- Altered Expression of Immune-Related Genes
- Altered IFN-γ Levels
- Altered Immune Response
- Altered Innate Immune Response
- Altered NF-kappaB Signaling
- Altered Pro-Inflammatory Cytokine Levels
- Altered Serum IL-6 Levels
- Altered Serum Immune Protein Levels
- Altered Systemic Immune Response
- Altered T Cell Migratory Behavior
- Altered T Cell Subsets
- Balanced T-Cell Differentiation
- Balanced Treg/Th17 Regulation
- Changes in Inflammatory Markers
- Chronic Immune Activation
- Decreased Naïve CD45RA+ T Helper Cells
- Decreased TNF-α Production in Immune Cells
- Delayed Onset of Thrombocytopenia
- Delayed Osteoporosis Progression
- Downregulated Complement System Activity
- Elevated BSA Antibody Levels
- Elevated Blood Cytokine Levels
- Elevated Complement C3 Levels
- Elevated IL-10 Levels
- Elevated IgG1 Levels
- Elevated Interferon-β Levels
- Elevated Interleukin-10 Levels
- Elevated Interleukin-12 Levels
- Elevated Interleukin-6 Levels
- Elevated Plasma Immunoglobulin M Levels
- Elevated Serum IFN-γ Levels
- Elevated Serum IL-2 Levels
- Elevated Serum IgM Levels
- Elevated Serum Total Ig Levels
- Elevated Total IgM Levels
- Enhanced Alternative Complement Activity
- Enhanced Anti-inflammatory Cytokine Expression During Healing
- Enhanced Anti-inflammatory Properties
- Enhanced B-Cell Proliferation
- Enhanced Cell-Mediated Immunity
- Enhanced Complement Pathway Activity
- Enhanced Cytokine Response
- Enhanced Dendritic Cell-T Cell Interaction
- Enhanced Immune Cell Activity
- Enhanced Immune Function
- Enhanced Immune Function Post-Cessation
- Enhanced Immune Function Post-Intervention
- Enhanced Immune Memory
- Enhanced Immune Modulation
- Enhanced Immune Regulation
- Enhanced Immune Response
- Enhanced Immune Response Regulation
- Enhanced Immune Signaling Molecule Production
- Enhanced Immune Status
- Enhanced Immune System Function
- Enhanced Immunity
- Enhanced Immunogenicity
- Enhanced Immunomodulation
- Enhanced Immunomodulatory Function
- Enhanced Immunoregulatory Function
- Enhanced Immunoregulatory Molecule Activity
- Enhanced Inflammation Resolution
- Enhanced Inflammatory Response
- Enhanced Interleukin-10 Production
- Enhanced Lymphocyte Proliferation
- Enhanced Negative Regulation of TLR Activity
- Enhanced Phagocytic Activity
- Enhanced Phenoloxidase Activity
- Enhanced Protection Against Streptococcal Infection
- Enhanced Regulatory Immune System Development
- Enhanced Regulatory T Cell Development
- Enhanced Regulatory T Cell Function
- Enhanced Serum ACH50 Activity
- Enhanced Serum Metabolite Levels Against Inflammation
- Enhanced Spleen Cell Proliferative Response
- Enhanced T Cell Activation
- Enhanced T- and B-Lymphocyte Proliferation
- Enhanced T-Cell Response
- Improved Alternative Complement Pathway Activity
- Improved Antigen Presentation
- Improved Antigen-Presenting Ability of Dendritic Cells
- Improved Antioxidant Function
- Improved Antioxidant and Anti-Inflammatory Response
- Improved B Cell Recovery
- Improved Cellular Immune Response
- Improved Cellular Immunity
- Improved Clinical Disease Activity
- Improved Complement C3 Level
- Improved Complement C4 Level
- Improved Cyclophosphamide-Induced Immunosuppression
- Improved Cytokine Levels
- Improved Cytokine Production
- Improved Disease Activity Index Score
- Improved Diversification of B-Cell Populations
- Improved Dry Eye Symptoms
- Improved Fatigue
- Improved Humoral Immune Parameters
- Improved Humoral Immunity
- Improved IL-10/TNF-α Ratio
- Improved Immune Activation
- Improved Immune Cell Counts
- Improved Immune Cell Function
- Improved Immune Homeostasis
- Improved Immune Modulation
- Improved Immune Organ Development
- Improved Immune Parameters
- Improved Immune Regulation
- Improved Immune Response to Influenza A
- Improved Immune Surveillance
- Improved Immune System Dialog via EPS
- Improved Immune System Function via JAK-STAT Pathway Activation
- Improved Immune System Maturation
- Improved Immune Tolerance
- Improved Immune-Related Symptoms
- Improved Immunity Pathways
- Improved Immunity Status
- Improved Immunoglobulin Levels
- Improved Immunoinflammatory Markers
- Improved Immunological Biomarkers
- Improved Immunomodulation
- Improved Immunostimulatory Activity
- Improved Inflammation Homeostasis
- Improved Inflammatory Marker Profile
- Improved Inflammatory Profile
- Improved Inflammatory Regulation
- Improved Inflammatory Status
- Improved Innate Humoral Immunity
- Improved Interleukin-10 Levels
- Improved Monocyte Activation
- Improved Multisystem Symptoms
- Improved Patient Global Assessment
- Improved Peripheral Blood Lymphocyte Proliferation
- Improved Peripheral Inflammation
- Improved Physician Global Assessment
- Improved Pre-Mortality General Health Score
- Improved Regulatory T Cell Function
- Improved Saliva Flow Rate
- Improved Seizure Control
- Improved Splenetic NK Cell Activity
- Improved Systemic Immune Response
- Improved Systemic Immunity
- Improved T Lymphocyte Subset Balance
- Improved T-Cell Cytokine Production
- Improved Th1/Th2 Balance
- Improved Tissue Pathology
- Improved Treg/Th-17 Balance
- Improved Vaccine Response in Immunocompromised Hosts
- Increased Activation of Regulatory T Cells
- Increased Anti-Inflammatory Cytokine IL-10
- Increased Anti-Inflammatory Cytokine IL-6 Production
- Increased Anti-Inflammatory Cytokine Levels
- Increased Anti-Inflammatory Immune Cell Populations
- Increased Anti-Osteoclastogenic Cytokine Production
- Increased Anti-inflammatory Phenotype in Dendritic Cells
- Increased Antigen-Presenting Cell Activation
- Increased Antigen-Specific IgG1 Levels
- Increased Apoptosis in T Cells
- Increased B Cell Activation
- Increased B Cell Count
- Increased B Cell Populations
- Increased Bone Marrow Myelopoiesis
- Increased C-Reactive Protein Level
- Increased CCL-20 Levels
- Increased CD4+ and CD8+ T Cell Proportion
- Increased CD4-Positive T-Lymphocytes
- Increased CD8 Percentage
- Increased Complement Component Levels
- Increased Complement Pathway Activity
- Increased Cytokine Production in Peripheral Blood Mononuclear Cells
- Increased Cytokine Response
- Increased Expression of Activation Markers on NK Cells
- Increased Ferritin Level
- Increased Follicular Helper T Cell Activity
- Increased Foxp3 Protein Levels
- Increased Foxp3+ to IL-10 Ratio
- Increased Generation of T Regulatory Cells
- Increased Helper T Cell Activation
- Increased Hemocyte Density
- Increased IFN-γ Levels
- Increased IFN-γ to IL-4 Ratio
- Increased IL-10 Concentration
- Increased IL-10 Levels
- Increased IL-10 Production
- Increased IL-12 Production
- Increased IL-12 Production in Splenocytes
- Increased IL-17 Levels
- Increased IL-2 Secretion
- Increased IgM Concentration
- Increased Immune Activation without Cytotoxicity
- Increased Immune Cell Presence
- Increased Immune Factor Levels
- Increased Immune Marker Levels
- Increased Immune Response
- Increased Immune System Activation
- Increased Immunoglobulin G Levels
- Increased Immunoglobulin G1 Levels
- Increased Immunoglobulin G2 Levels
- Increased Immunoglobulin Levels
- Increased Immunoglobulin M Levels
- Increased Immunosuppressive Cytokine Production
- Increased Inflammatory Cytokines
- Increased Inflammatory Mediator Production
- Increased Interferon Beta Levels
- Increased Interferon-Alpha Production
- Increased Interferon-Gamma Levels
- Increased Interleukin 12 Secretion from Dendritic Cells
- Increased Interleukin-10 Levels
- Increased Interleukin-10 Production
- Increased Interleukin-12p40 Production
- Increased Interleukin-2 Production
- Increased LL-37 Levels
- Increased Lymphoid Cell Proliferation in Germ-Free Animals
- Increased Memory T Cell Frequency
- Increased Peripheral Blood B Cell Frequency
- Increased Plasma Anti-inflammatory Cytokine Levels
- Increased Plasma Immunoglobulin Levels
- Increased Pro-inflammatory Cytokine TNFα Levels
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Proportion of Activated T Lymphocytes
- Increased Proportion of CD45R+ B-cells
- Increased Proportion of T Lymphocytes
- Increased Regrowing Hair Count
- Increased Regulatory T Cell Expansion
- Increased Regulatory T Cell Frequency
- Increased Regulatory T Cell Induction
- Increased Regulatory T Cell Populations
- Increased Regulatory T Cell Response
- Increased Regulatory T-Cells
- Increased Serum Alternative Complement Activity
- Increased Serum IL-10 Levels
- Increased Serum IgM Levels at 30 Days
- Increased Serum Immunoglobulin Levels
- Increased Serum Immunoglobulins
- Increased Serum Tumor Necrosis Factor-α Levels
- Increased Short-Term Serum IgM Levels
- Increased Specific Antibody Production
- Increased Specific IgG Levels
- Increased Splenic Lymphocyte Proliferation
- Increased Systemic Antibody Production
- Increased T Cell Activation
- Increased T-cell Proliferation at 12 Months
- Increased TNF-alpha Levels in Macrophages
- Increased TNF-α Production
- Increased Tolerogenic Dendritic Cells
- Increased Total Coelomocyte Count
- Increased Transforming Growth Factor-β Levels
- Increased Treg Cell Fraction
- Increased Treg Frequency at 7 Days
- Increased Tumor Necrosis Factor-Alpha Production by Dendritic Cells
- Increased Type 1 Collagen Synthesis
- Increased Type I Interferon Production
- Induced Immunomodulatory Effects
- Inflammatory Disease Protection
- Influenced Systemic Immune Response
- Inhibited Autoimmune Activation
- Inhibited IκBα Degradation
- Maintained Immune Homeostasis
- Matured Antigen-Presenting Cells
- Modulated Cytokine Levels
- Modulated Cytokine Production
- Modulated Dendritic Cell Function
- Modulated Host Immune Response
- Modulated Humoral Inflammation
- Modulated Immune Function in Offspring
- Modulated Immune Markers
- Modulated Immune Response
- Modulated Immune System
- Modulated Immune Tolerance
- Modulated Immunoinflammatory Parameters
- Modulated Immunologic Response
- Modulated Immunological Profile
- Modulated Inflammation and Coagulation Interaction
- Modulated Inflammatory Cytokine Levels
- Modulated Innate Immune Response
- Modulated Lymphocyte Populations
- Modulated Peripheral Immune Response
- Modulated Systemic Immune Response
- Modulated Systemic Th1/Th2 Balance
- Modulated T Cell Response
- No Change in C-Reactive Protein
- No Change in Proinflammatory Cytokine Secretion
- No Change in Vaccine Responses
- No Meaningful Change in IL-10
- No Meaningful Change in IL-8
- No Measurable IFN-Alpha Induction
- No Significant Change in Tumor Necrosis Factor Alpha Levels
- No Significant Effect on C-Reactive Protein Levels
- Normalized Serum IL-10 Levels
- Prevention of Aberrant Inflammatory Response
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced Activated B Cells
- Reduced Allograft Rejection
- Reduced Anti-dsDNA Positivity
- Reduced B Cell Count in Draining Lymph Nodes
- Reduced B Lymphocyte Proliferation
- Reduced Blood Clot Formation
- Reduced C-Reactive Protein Level
- Reduced CD25+ Cells
- Reduced CD28 Expression Loss in CD8+ T Cells
- Reduced CD8 Cell Percentage
- Reduced CTLA-4 Expression on CD4 T Cells
- Reduced CTLA-4 Induction on CD4 T Cells
- Reduced Catalase Activity
- Reduced Cervical Lymphadenopathy Symptoms
- Reduced Circulating Monocytes
- Reduced Complement Component 1q Level
- Reduced Corticosteroid Usage
- Reduced Cytokine Secretion in Dendritic Cells
- Reduced Cytotoxic Effects
- Reduced Debridement Time
- Reduced Dendritic Cell Function
- Reduced Disease Activity
- Reduced Disease Activity Index Scores
- Reduced Fas Level
- Reduced Fatigue Severity
- Reduced Germinal Center B Cells in Draining Lymph Nodes
- Reduced Granulocyte Levels
- Reduced High-Sensitivity C-Reactive Protein Level
- Reduced Histopathological Damage
- Reduced IFN-γ in Serum
- Reduced IL-12p70 Release
- Reduced IL-17 Production in Splenocytes
- Reduced IL-1β Levels
- Reduced IL-6 Concentration
- Reduced IL-6 Levels
- Reduced IL-6 Secretion
- Reduced IL-8 Secretion
- Reduced Immune Activation
- Reduced Immune Cell Activity
- Reduced Immune Cell Infiltration
- Reduced Immune Protection
- Reduced Immune-Mediated Pathologies
- Reduced Immunological Pathway Activity in Antigen Presentation
- Reduced Infection Frequency
- Reduced Inflammation in Dendritic Cells
- Reduced Inflammatory Activities
- Reduced Inflammatory Cell Activity
- Reduced Inflammatory Cytokine Secretion from Activated T Cells
- Reduced Inflammatory Cytokines (TNF-α, IFN-γ, IL-6)
- Reduced Inflammatory Diseases
- Reduced Inflammatory Effects
- Reduced Inflammatory Immune Mediators
- Reduced Inflammatory Marker Protein Levels
- Reduced Inflammatory Markers in Aqueous Humour
- Reduced Inflammatory Mediators
- Reduced Inflammatory Pathway Activity
- Reduced Inflammatory Processes
- Reduced Inflammatory Protein Activation
- Reduced Inflammatory Response
- Reduced Inflammatory Response to Inflammatory Stimulus
- Reduced Inflammatory Stimulators
- Reduced Inflammatory Tone
- Reduced Innate Immune Cell Activation
- Reduced Interleukin-1 Beta Level
- Reduced Interleukin-10 Levels
- Reduced Interleukin-17 Level
- Reduced Interleukin-1β Concentration
- Reduced Interleukin-1β Levels
- Reduced Interleukin-22 Level
- Reduced Interleukin-6 Levels
- Reduced LPS-Induced Cellular Activity
- Reduced Levels of Anti-Inflammatory Cytokines
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Lupus Disease Activity
- Reduced Lupus-Associated Renal Damage
- Reduced Lymphocytic Genome Damage
- Reduced MAPK Activation
- Reduced Monocyte Chemoattractant Protein-1 Level
- Reduced Mycobacterium bovis BCG Phagocytic Uptake
- Reduced Naïve CD45RA+ Th Cell Count
- Reduced Neutrophil Extracellular Trap Formation
- Reduced Neutrophil Infiltration
- Reduced Nonclassical Monocyte Frequency
- Reduced Oral Aphthosis Frequency
- Reduced Organ Damage
- Reduced Oxidative Damage in Serum
- Reduced Oxidative Stress in Red Blood Cells
- Reduced Pathogen Resistance
- Reduced Peak Body Temperature During Flares
- Reduced Perinatal Loss
- Reduced Peripheral Inflammation
- Reduced Phospho-p65 Translocation
- Reduced Plasma Anti-dsDNA Levels
- Reduced Plasma IL-10 Levels
- Reduced Plasma IgG Production
- Reduced Plasma Tumor Necrosis Factor-α Levels
- Reduced Pro-Inflammatory Cytokine Synthesis
- Reduced Pro-Inflammatory Cytokines
- Reduced Pro-Inflammatory Factor TNF-α
- Reduced Pro-Inflammatory Immune Activity
- Reduced Pro-inflammatory Cytokine Interleukin-8 Levels
- Reduced Pro-inflammatory Cytokine Release
- Reduced Pro-inflammatory Effect
- Reduced Pro-inflammatory Gene Transcription
- Reduced Pro-inflammatory Immune Responses
- Reduced Proinflammatory Cytokine Production
- Reduced Proinflammatory Cytokine Secretion
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proinflammatory Cytokines in Middle-aged Adults
- Reduced Proinflammatory Factor Levels
- Reduced Proinflammatory Factors
- Reduced Proinflammatory Profile
- Reduced Proinflammatory/Anti-inflammatory Cytokine Ratios
- Reduced Recurrent Implantation Failure
- Reduced Release of Inflammatory Mediators (TNF-α, IL-6, IL-1β, IL-10)
- Reduced Risk Factors for Multiple Sclerosis
- Reduced Serum Cytokine Levels
- Reduced Serum IL-16 Levels
- Reduced Serum TNF-Alpha Level
- Reduced Serum Tumor Necrosis Factor-α
- Reduced Soluble VCAM-1 Levels
- Reduced Steroid Load
- Reduced Systemic Inflammatory Response
- Reduced Systemic Lupus Erythematosus Disease Activity Index Score
- Reduced T Cell Proliferation
- Reduced T-Effector Memory Cell Activity
- Reduced TLR Inflammatory Activation
- Reduced TNF-α Concentration
- Reduced TNF-α Levels
- Reduced Th17 Cell Fraction
- Reduced Thrombocytopenia
- Reduced Total Immune Cells in Draining Lymph Nodes
- Reduced Total White Blood Cell Counts
- Reduced Transforming Growth Factor Beta Levels
- Reduced Tumor Necrosis Factor-α (TNF-α)
- Reduced White Blood Cell Count
- Reduced miR-155 Level
- Regulated Cytokine Levels
- Regulated Immune Cell Proliferation
- Regulated Immune Response
- Regulated Inflammation
- Regulated Inflammatory Markers
- Regulated Inflammatory Process
- Regulated Systemic Immune Response Imbalance
- Restored Immune Organ Structure
- Restored Regulatory T Cell Population
- Restored T-Cell Population
- Restored Th1/Th2 Cytokine Balance
- Restored Treg Cell Population in MLNs
- Reversed Thymic Atrophy
- Stabilized Cytokine Levels
- Stable Immune System Responses
- Stable Inflammatory Responses
- Stable Systemic Inflammatory Response
- Stimulation of Immune Cells
- Suppressed Inflammatory Chemokine Secretion
- Suppressed TNF-α Induced Genes
- Sustained Anti-Inflammatory Gene Transcription
- Sustained Immune Activity
- Sustained Immune Function
- Unchanged Inflammatory Marker Production
- Unchanged Spleen Weight Index